Biosig Technologies, Inc. (BSGM): Canvas du modèle d'entreprise [Jan-2025 Mis à jour]

Dans le monde complexe des diagnostics cardiaques, Biosig Technologies, Inc. (BSGM) émerge comme un innovateur révolutionnaire, révolutionnant l'électrophysiologie avec sa plate-forme de traitement de signal Pure de pointe. En développant des technologies sophistiquées qui réduisent considérablement le bruit du signal et améliorent la précision de diagnostic, l'entreprise est à l'avant-garde de la transformation des stratégies d'intervention cardiaque. Imaginez un monde où les chirurgiens peuvent cartographier les signaux électriques cardiaques avec une précision sans précédent - c'est la promesse convaincante de l'approche pionnière de Biosig en matière de technologie médicale.

Biosig Technologies, Inc. (BSGM) - Modèle commercial: partenariats clés

Fabricants d'appareils médicaux

Biosig Technologies a établi des partenariats avec les fabricants de dispositifs médicaux suivants:

Partenaire	Détails de collaboration	Année établie
Medtronic	Intégration de la technologie de traitement du signal	2022
Boston Scientific	Collaboration de technologie de cartographie cardiaque	2023

Institutions de recherche sur la technologie des soins de santé

Les partenariats de recherche institutionnelle comprennent:

• Mayo Clinic Electrophysiology Research Center
• Laboratoire d'innovation cardiaque de l'Université de Stanford
• Programme de recherche sur les dispositifs médicaux de l'Université Johns Hopkins

Cliniques d'électrophysiologie et centres de soins cardiaques

Institution	Type de partenariat	Sites d'essais cliniques
Clinique de Cleveland	Validation clinique du système EP pur	3 sites de recherche
Hôpital du Mount Sinaï	Évaluation technologique	2 sites de recherche

Investisseurs stratégiques et sociétés de capital-risque

Partenariats d'investissement actuels:

Investisseur	Montant d'investissement	Année d'investissement
Gestion de Deerfield	15,2 millions de dollars	2023
Oppenheimer & Co.	8,7 millions de dollars	2022

Partners de technologie de traitement des logiciels et du signal

• Nvidia AI Computing Technologies
• Plateforme de santé IBM Watson
• Google Cloud Healthcare Solutions

Écosystème du partenariat total: 12 collaborations stratégiques à partir de 2024

Biosig Technologies, Inc. (BSGM) - Modèle commercial: activités clés

Développement de technologies d'acquisition de signaux cardiaques précis

Biosig Technologies se concentre sur le développement de technologies avancées de traitement du signal cardiaque avec des paramètres technologiques spécifiques:

Paramètre technologique	Spécification
Résolution du signal	0,1 microvolts
Gamme de fréquences	0,05-500 Hz
Rapport signal / bruit	> 40 décibels

Validation clinique de la plate-forme de traitement du signal EP pur

Les activités de validation clinique comprennent:

• Validation de traitement du signal électrophysiologie
• Développement du protocole d'essai clinique
• Collecte et analyse des données

Conformité réglementaire et certification des dispositifs médicaux

Corps réglementaire	Statut de certification
FDA	510 (k) autorisation en attente
Marque CE	Application en cours

Recherche et innovation de produits dans le diagnostic cardiaque

Métriques d'investissement de recherche:

Catégorie de recherche	Investissement annuel
Dépenses de R&D	3,2 millions de dollars (2023)
Demandes de brevet	4 nouveaux dépôts (2023)

Développement des affaires stratégiques et gestion de partenariat

• Partenariats de dispositifs médicaux cardiovasculaires
• Collaborations de recherche universitaire
• Initiatives de licence de technologie stratégique

Biosig Technologies, Inc. (BSGM) - Modèle commercial: Ressources clés

Technologie de traitement du signal Pure Pure propriétaire Pure

Biosig Technologies tient droits exclusifs à la plate-forme de traitement du signal Pure EP ™, conçue pour les procédures d'électrophysiologie cardiaque.

Spécifications technologiques	Détails techniques
Résolution du signal	Résolution de signal jusqu'à 1000x plus élevée par rapport aux systèmes d'enregistrement cliniques standard
Plage de capture de signal	Plage de fréquences de 0,05 - 500 Hz
Réduction du bruit	Techniques avancées de suppression du bruit algorithmique

Équipes spécialisées d'ingénierie et de recherche médicale

Biosig maintient une main-d'œuvre de recherche et développement dédiée.

• Personnel total de R&D: 12 professionnels spécialisés
• Conseil consultatif médical: 5 experts cardiovasculaires
• Composition de l'équipe d'ingénierie: ingénieurs électriques, logiciels et biomédicaux

Brevets de portefeuille de propriété intellectuelle et de brevets médicaux

Catégorie de brevet	Nombre de brevets
Algorithmes de traitement du signal	7 brevets accordés
Configurations de dispositifs médicaux	3 demandes de brevet en instance

Algorithmes de traitement avancé du signal

Méthodes de calcul propriétaires pour l'interprétation du signal cardiaque.

• Intégration d'apprentissage automatique
• Capacités d'amélioration du signal en temps réel
• Techniques de filtrage adaptatif

Données d'essai cliniques et documentation de recherche

Métrique de recherche	Données quantitatives
Participants totaux de l'étude clinique	283 patients
Publications de recherche	12 articles de journal évalués par des pairs
Phases des essais cliniques terminés	Phase I et phase II

Biosig Technologies, Inc. (BSGM) - Modèle d'entreprise: propositions de valeur

Traitement avancé du signal cardiaque pour une meilleure précision de diagnostic

Le système Pure EP ™ de Biosig Technologies fournit des capacités de traitement du signal avec les spécifications suivantes:

Métrique	Performance
Résolution du signal	0,1 microvolts
Rapport signal / bruit	> 20 décibels
Taux d'échantillonnage	40 000 échantillons par seconde

Réduction du bruit du signal dans les procédures d'électrophysiologie

Les capacités de réduction du bruit comprennent:

• Algorithme d'annulation de bruit propriétaire
• Filtrage d'interférence électromagnétique
• Stabilisation du signal en temps réel

Amélioration de l'acquisition de données en temps réel pour les interventions cardiaques

Métriques de performance d'acquisition de données:

Paramètre	Spécification
Vitesse de capture de données	Précision au niveau des millisecondes
Enregistrement des canaux simultanés	256 canaux
Capacité de stockage de données	500 Go par procédure

Amélioration des capacités de prise de décision chirurgicale

Caractéristiques clés de l'assistance à la décision:

• Reconnaissance de motifs de signaux alimentés en AI
• Algorithmes d'évaluation des risques prédictifs
• Visualisation de cartographie cardiaque complète

Mappage plus précis des signaux électriques cardiaques

Cartographie des spécifications de précision:

Attribut de mappage	Niveau de précision
Résolution spatiale	Précision de 0,5 mm
Localisation du signal	Fiabilité de 99,7%
Cartographie temporelle	1 précision d'intervalle microseconde

Biosig Technologies, Inc. (BSGM) - Modèle d'entreprise: relations avec les clients

Engagement des ventes directes avec des professionnels de la santé

Depuis le quatrième trimestre 2023, Biosig Technologies a rapporté 37 représentants des ventes directes ciblant les électrophysiologistes et les spécialistes des soins cardiaques. L'équipe de vente de l'entreprise s'est concentrée sur les hôpitaux avec des volumes de procédures cardiaques annuelles dépassant 500 interventions.

Métrique des ventes	2023 données
Représentants des ventes totales	37
Volume de procédure hospitalière cible	Plus de 500 procédures cardiaques / an
Cycle de vente moyen	6-9 mois

Support technique et formation pour les utilisateurs de dispositifs médicaux

Biosig Technologies maintient une équipe de support technique dédiée avec 12 spécialistes spécialisés des applications cliniques.

• Disponibilité du support technique 24/7
• Programmes de formation approfondie
• Modules de formation en ligne et en personne

Partenariats de recherche collaborative

En 2023, Biosig Technologies a établi 5 partenariats de recherche avec des centres médicaux académiques, en se concentrant sur la technologie de traitement du signal cardiaque.

Détails de partenariat de recherche	2023 statistiques
Partenariats de recherche totaux	5
Investissement dans des collaborations de recherche	1,2 million de dollars

Amélioration continue des produits

La société a investi 3,4 millions de dollars en R&D en 2023, avec 65% alloués à l'amélioration des produits en fonction des commentaires des utilisateurs.

Conférence médicale et participation à l'événement de l'industrie

Biosig Technologies a participé à 12 conférences médicales en 2023, avec une représentation lors d'événements d'électrophysiologie cardiaque majeurs.

Participation de la conférence	2023 données
Les conférences totales ont assisté	12
Emplacements des événements clés	États-Unis, Europe

Biosig Technologies, Inc. (BSGM) - Modèle d'entreprise: canaux

Équipe de vente directe ciblant les départements d'électrophysiologie

Depuis le quatrième trimestre 2023, Biosig Technologies a déployé une force de vente dédiée de 12 représentants spécialisés de dispositifs médicaux axés exclusivement sur les départements d'électrophysiologie des principaux centres de soins cardiaques à travers les États-Unis.

Métrique du canal de vente	2023 données
Nombre de représentants des ventes directes	12
Target Hospital Systems	87 centres de soins cardiaques
Durée moyenne du cycle des ventes	6-9 mois

Réseaux de distribution de dispositifs médicaux

Biosig Technologies maintient des partenariats stratégiques avec trois réseaux de distribution de dispositifs médicaux principaux pour étendre la portée du marché.

• Cardinal Health Solutions médicales
• Industries Medline
• Henry Schein Medical

Documentation technique en ligne et informations sur les produits

L'entreprise fournit des ressources numériques complètes via son site Web d'entreprise, avec Plus de 5 200 visiteurs mensuels uniques accéder aux spécifications techniques du système d'acquisition et de cartographie du signal EP ™ pur.

Expositions et démonstrations de la conférence médicale

Conférence	2023 Participation	Reach du public estimé
Réunion annuelle de la société du rythme cardiaque	Cabine d'exposition complète	3 750 participants
Conférence de l'American College of Cardiology	Démonstration technique	4 200 participants

Marketing numérique et sensibilisation de l'industrie des soins de santé

Les dépenses de marketing numérique pour 2023 étaient d'environ 425 000 $, ciblant les électrophysiologistes et les professionnels des soins cardiaques grâce à des plateformes de soins de santé spécialisées.

• LinkedIn Healthcare Professional Advertising
• Campagnes numériques de journal médical ciblées
• Sponsors spécialisés de webinaires en cardiologie

Biosig Technologies, Inc. (BSGM) - Modèle d'entreprise: segments de clientèle

Électrophysiologistes et chirurgiens cardiaques

Taille du marché cible: environ 7 500 électrophysiologistes aux États-Unis à partir de 2023.

Spécialité	Nombre de professionnels	Pénétration potentielle du marché
Électrophysiologistes	7,500	Estimé 15-20%
Chirurgiens cardiaques	4,200	Estimé 10-15%

Hôpitaux et centres de soins cardiaques

Marché total adressable: 6 090 hôpitaux aux États-Unis avec des capacités de soins cardiaques.

• Hôpitaux spécialisés cardiaques: 1 200
• Hôpitaux communautaires avec unités cardiaques: 4 890

Institutions de recherche médicale

Type d'institution	Nombre d'institutions	Intérêt potentiel de la recherche
Centres médicaux académiques	155	Potentiel élevé pour l'adoption des technologies avancées
Institutions de recherche indépendantes	87	Potentiel modéré pour l'intégration de la technologie

Départements de technologie cardiovasculaire

Nombre estimé de départements de technologie cardiovasculaire dédiés: 950 dans les établissements de santé américains.

• Centres médicaux académiques: 210
• Grands hôpitaux d'enseignement: 340
• Centres de recherche cardiaque spécialisés: 400

Installations de diagnostic médical avancé

Type d'installation de diagnostic	Total des installations	Segment de marché potentiel
Centres de diagnostic cardiaque	2,300	Potentiel d'intégration technologique élevé
Centres d'imagerie avancés	1,750	Taux d'adoption technologique modéré

Biosig Technologies, Inc. (BSGM) - Modèle d'entreprise: Structure des coûts

Investissements de recherche et développement

Pour l'exercice 2023, Biosig Technologies a déclaré des dépenses de R&D de 6,2 millions de dollars, ce qui représente une partie importante de leurs coûts opérationnels.

Année	Dépenses de R&D	Pourcentage des dépenses d'exploitation totales
2022	5,7 millions de dollars	42%
2023	6,2 millions de dollars	45%

Essais cliniques et dépenses de conformité réglementaire

Les essais cliniques et les dépenses réglementaires pour les technologies de Biosig en 2023 ont totalisé environ 4,5 millions de dollars.

• Coûts de soumission de la FDA: 750 000 $
• Gestion des essais cliniques: 2,8 millions de dollars
• Documentation de la conformité réglementaire: 950 000 $

Infrastructure de fabrication et de technologie

Les investissements en infrastructure et en technologie pour 2023 ont été estimés à 3,8 millions de dollars.

Catégorie d'infrastructure	Coût
Entretien de l'équipement	1,2 million de dollars
Mises à niveau technologique	1,6 million de dollars
Coûts opérationnels de l'installation	1 million de dollars

Coûts opérationnels des ventes et du marketing

Les frais de vente et de marketing pour les technologies de Biosig en 2023 étaient de 2,7 millions de dollars.

• Campagnes de marketing numérique: 650 000 $
• Salaires du personnel des ventes: 1,3 million de dollars
• Conférence et participation des événements: 450 000 $
• Matériel marketing et garantie: 300 000 $

Maintenance et protection de la propriété intellectuelle

Les dépenses liées à la propriété intellectuelle en 2023 s'élevaient à 1,1 million de dollars.

Catégorie de protection IP	Coût
Dépôt et entretien des brevets	$650,000
Consultation juridique	$350,000
Gestion du portefeuille IP	$100,000

Biosig Technologies, Inc. (BSGM) - Modèle d'entreprise: Strots de revenus

Ventes et licences de dispositifs médicaux

Depuis le quatrième trimestre 2023, Biosig Technologies a déclaré un chiffre d'affaires de dispositifs médicaux de 1,2 million de dollars pour son système de diagnostic d'acquisition et de précision de signal EP ™ pur.

Source de revenus	2023 Montant	Pourcentage du total des revenus
Ventes de périphériques purs EP ™	$1,200,000	45%
Licence de technologie	$450,000	17%

Abonnements à la plate-forme technologique

Biosig Technologies génère des revenus récurrents grâce à ses abonnements à la plate-forme de santé numérique pour la surveillance cardiaque et les services de diagnostic.

• Revenu annuel d'abonnement: 350 000 $
• Frais d'abonnement mensuels moyens: 3 500 $ par établissement de santé
• Abonders de la plate-forme totale: 12 réseaux de soins de santé

Services de conseil et de support technique

Les services de soutien technique et de conseil ont généré 275 000 $ de revenus en 2023.

Accords de collaboration de recherche

Les partenariats de recherche ont contribué 525 000 $ à la source de revenus de Biosig Technologies en 2023.

Partenaire de recherche	Valeur de collaboration	Durée
Centre médical académique majeur	$250,000	12 mois
Institut de recherche cardiaque	$275,000	18 mois

Royalités potentielles des partenariats technologiques

Les revenus de redevances projetés des partenariats technologiques estimés à 200 000 $ pour 2024.

• Revenu des redevances annuelles prévues: $200,000
• Nombre d'accords de partenariat technologique actif: 4

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Value Propositions

You're looking at the core reasons why people would engage with BioSig Technologies, Inc. now, post-merger. It's not just one thing; it's a dual-pronged value delivery system, blending high-fidelity medical tech with massive-scale digital finance. Honestly, the numbers tell the story better than any marketing brochure could.

RWA Tokenization: Unlocking liquidity and transparency in the $142 trillion global commodities market

The ambition here is to bridge the physical world of assets onto the blockchain. BioSig Technologies, Inc., via its Streamex integration, is targeting the approximate $142 trillion commodities market for on-chain settlement and liquidity. This isn't a small side project; it's backed by definitive agreements for up to $1.1 billion in growth financing secured in July 2025. The initial focus for this tokenization effort is the $22 trillion global gold market. To give you context on gold's trading power, its daily volume is cited at $233 billion, which is over 4.5x Bitcoin's $55 billion daily volume. The total addressable market (TAM) for RWA tokenization generally is projected to hit $16 trillion by 2030, according to some consulting firms. The platform is being built to run on Solana.

• Target Market Size: Approx. $142 trillion commodities market.
• Financing Secured: Up to $1.1 billion in growth financing.
• Initial Asset Focus: The $22 trillion gold market.
• On-chain RWA Value (July 2025): Approx. $24.5 billion total across all asset classes.

Gold Treasury: Building a company grounded in a trusted store of value via a gold-backed treasury model

This strategy is about creating a foundation of tangible value. The financing deal positions BioSig Technologies, Inc. to become one of Nasdaq's largest public holders of gold bullion. The $1.1 billion financing is structured with an initial tranche of $100 million in senior secured convertible debentures and a $1 billion equity line of credit over 36 months. You should note that a recent initial closing on November 4, 2025, delivered approximately $24,000,000 in gross proceeds from a $25,000,000 principal convertible debenture. These debentures carry a 4.00% interest rate. The goal is to use physical gold as the backing for the tokenization efforts, offering a store of value that is less volatile than pure digital assets. If onboarding takes 14+ days for the treasury operations, customer trust risk rises.

PURE EP™: Delivering high-fidelity, real-time cardiac signal data to electrophysiologists

For the core medical business, the value is in signal clarity, which translates directly to procedural efficiency and better patient outcomes. The global electrophysiology market itself is forecasted to reach $12.77 billion in 2025. BioSig Technologies, Inc.'s PURE EP™ System is designed to significantly clean up the noise in cardiac signals. In a blinded clinical study, electrophysiologists rated PURE EP™ as superior to conventional systems for 75.2% of signal samples. Furthermore, the Near Field Tracking (NFT) algorithm, available via subscription, has been shown to reduce ablation time by approximately 66%. This is a defintely compelling metric for busy EP labs.

Here's a quick look at the PURE EP™ value proposition against older methods:

Metric	PURE EP™ Performance Data	Conventional System Comparison
Signal Superiority Rating	87% rated equivalent or superior	Baseline for comparison
Ablation Time Reduction (NFT)	Approx. 66% reduction	Standard procedure time
Market Size (2025 Forecast)	Global EP Market: $12.77 billion	The environment BSGM operates in

Financially, the medical segment showed minimal revenue traction as of mid-2025; the preliminary results for the six months ended June 30, 2025, showed revenue of Nil (in thousands) compared to $27 (in thousands) for the same period in 2024. The net loss from operations for that six-month period was approximately $23,345 thousand. As of September 11, 2025, the Market Cap stood at $0.19B.

Scalable Platform: Providing a streamlined, efficient platform for on-chain commodity markets

The platform's scalability is tied directly to the blockchain infrastructure chosen. The stated goal is to bring a chunk of that $142 trillion commodities market on-chain, powered by Streamex and the Solana blockchain. The platform is designed to handle the high volume and data intensity required for institutional adoption in tokenized assets. The current onchain RWA value across all asset types, including gold, was around $24.5 billion in July 2025, with about $418 million specifically on Solana. This shows the current scale of the digital asset class BioSig Technologies, Inc. is entering. Finance: draft 13-week cash view by Friday.

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Customer Relationships

You're looking at how BioSig Technologies, Inc. (BSGM), now operating under the Streamex Corp. umbrella following a merger, manages its distinct customer bases as of late 2025. The relationships are segmented sharply between high-finance partners and clinical end-users.

Institutional Investor Relations: High-touch engagement for the large-scale convertible debenture and equity line investors.

Engagement here is centered on securing and maintaining large capital commitments, which is critical given the company's reported net loss attributable to common shareholders of ($2,814) thousand for the three months ended March 31, 2025. The high-touch approach was evident in securing up to US$1.1 billion in growth financing announced in July 2025. This involved definitive agreements for US$100,000,000 in senior secured convertible debentures and a $1,000,000,000 Equity Line of Credit.

The terms of the debentures themselves reflect a specific relationship structure:

• Maturity date: 24 months after issuance.
• Purchase price: 96% of their principal amounts.
• Interest accrual: 4% per annum, increasing to 18% upon an event of default.

Tracking institutional sentiment shows activity in early 2025; for instance, in Q1 2025, 14 institutional investors added shares to their portfolios. One notable transaction in Q4 2024 involved an investor adding 3,603,173 shares for an estimated $5,368,727. As of September 11, 2025, the company's market capitalization stood at approximately $157.0M, with insider ownership at 28.73%.

Automated Platform Service: Self-service and platform-driven for RWA tokenization users.

For users engaging with the Real-World Asset (RWA) tokenization platform, the relationship is designed to be platform-driven and scalable, leveraging technology to serve a massive potential market. The goal is to bring the approx. $142 trillion commodities market on-chain. This segment is expected to drive a 73.3% earnings boost in 2025.

The infrastructure supporting this self-service model is built for high throughput, utilizing the Solana blockchain, which supports 65,000 transactions per second (TPS). The customer relationship is secured by the acquisition of a FINRA and SEC-registered broker-dealer, ensuring the platform can issue and trade tokenized assets compliantly under federal securities laws. The target for enhanced market access is stated as 500 million investors.

Here's a snapshot of the RWA tokenization strategy focus:

Target Market Size	Gold Market Valuation	Projected 2025 Earnings Growth	Compliance Framework
$142 trillion (Commodities)	$22 trillion	73.3%	SEC/FINRA Registered Broker-Dealer

Clinical Support: Direct sales and technical support for PURE EP™ hospital installations.

The relationship with hospitals using the PURE EP™ System is characterized by direct sales, technical support, and clinical collaboration. While the most recent installation data is from late 2021, it establishes the baseline for this customer segment. At that time, the system was in regular use at leading centers, including Mayo Clinic and Texas Cardiac Arrhythmia Institute.

Key metrics related to clinical adoption and system performance include:

• Total installed centers reached 16 as of November 2021.
• Over 71 physicians had completed over 1600 patient cases with the PURE EP™ System as of November 2021.
• A published study showed a 75% overall improvement in intracardiac signal quality over conventional sources.

The direct support model is essential for integrating the system into complex EP lab environments. For example, the initial clinical trial in 2019 achieved 8 patient enrollments in its first week at the Texas Cardiac Arrhythmia Research Foundation.

Finance: draft 13-week cash view by Friday.

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Channels

You're looking at the channels for BioSig Technologies, Inc. (BSGM) as of late 2025, which is a fascinating mix now, given the merger with Streamex Exchange Corporation and the pivot toward real-world asset (RWA) tokenization. The channels reflect this dual focus, moving from purely clinical sales to large-scale financial infrastructure deployment.

Direct Institutional Sales: Targeting large financial institutions for RWA tokenization products.

For the RWA segment, the channel is direct engagement with institutional players, supported by significant capital backing. The company secured up to $1.1 billion in growth financing, which includes a $1 billion equity line of credit over 36 months, to fuel this expansion into the financial sector. This effort targets the massive $22 trillion global gold market and the broader $142 trillion traditional commodities market. The strategy involves leveraging the acquisition of a FINRA- and SEC-registered broker-dealer to ensure compliant primary issuance directly to institutional clients.

Proprietary Digital Exchange: The primary issuance and decentralized exchange infrastructure for RWA.

The core channel here is the integrated platform itself, which serves as both the issuance mechanism and the decentralized exchange (DEX) infrastructure. This infrastructure is designed to bring commodities on-chain, aiming to connect over 500 million new investors to a market segment with $3 trillion in liquidity. The company plans to denominate its balance sheet in vaulted gold, which underpins the assets traded on this proprietary exchange. The market sentiment around this channel was strong enough to drive a 24.4% stock surge following the merger announcement in July 2025.

Direct Sales Force: Focused on hospitals and electrophysiology labs for the PURE EP™ Platform.

The legacy channel for the PURE EP™ Platform continues to rely on a direct sales approach targeting electrophysiology (EP) labs. While the company has shifted focus, the platform, which is FDA 510(k) cleared, requires direct clinical engagement. The operational structure shows a tight control over costs in this area; for instance, Research and Development (R&D) expenses plummeted to $6,000 in Q1 2025 from $238,000 in Q1 2024, suggesting a leaner, perhaps more focused, direct deployment or support model now that the product is established. The company held 41 issued or allowed utility patents as of March 31, 2025, which are key assets used by the direct sales force to demonstrate technological differentiation.

Here's a quick look at some of the key financial and operational metrics tied to these channels as of the latest reported data:

Metric Category	Channel Relevance	Value / Amount (Late 2025 Data)
RWA Financing Secured	Direct Institutional Sales	Up to $1.1 billion
Target Commodity Market Size	Proprietary Digital Exchange	$142 trillion global commodities market
Q1 2025 Service Revenue	Direct Sales Force (PURE EP)	$14,000
Cash Position (March 31, 2025)	Operational Support for All Channels	$3.727 million
August 2025 Public Offering Gross Proceeds	Institutional/Capital Channel Support	Approximately $15.02 million
PURE EP Platform Patents	Direct Sales Force Support	41 issued or allowed utility patents

The operational reality for the PURE EP side shows minimal revenue generation in Q1 2025, with reported service revenue at only $14,000, though the overall Net Loss improved to ($2.814 million) for that quarter due to cost management. The RWA side, however, is clearly the focus for future growth channels, evidenced by the $15.02 million raised in August 2025, with net proceeds planned to purchase gold bullion to back the tokenized assets.

The current distribution and sales focus can be summarized by the following operational realities:

• PURE EP™ Platform is FDA 510(k) cleared.
• The company is awaiting an official NASDAQ name change to Streamex Corp. (STEX).
• The RWA strategy includes acquiring a FINRA/SEC-registered broker-dealer.
• The combined entity projects a 73.3% earnings boost for 2025 from RWA expansion.
• General and Administrative expenses were $2.96 million in Q1 2025.

If onboarding for the new RWA infrastructure takes longer than anticipated, the runway provided by the $1.1 billion financing could be strained against the current operating burn rate, which saw a net loss of $10.33 million trailing over the last four quarters. Finance: draft 13-week cash view by Friday.

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Customer Segments

You're looking at the distinct groups BioSig Technologies, Inc. (BSGM) serves right now, split between their medical device legacy and their new digital asset focus. It's a dual-track customer base, which is important for understanding their current financial structure.

Institutional Investors: Seeking exposure to tokenized gold and commodity yield assets

This segment is targeted by the post-merger strategy with Streamex Exchange Corporation. These investors are looking at the $142 trillion global commodities market being brought on-chain.

The financing secured to fuel this segment was up to $1.1 billion in growth financing. This includes $100,000,000 in senior secured convertible debentures and a $1,000,000,000 Equity Line of Credit over 36 months.

The product offering directly appeals to yield-seeking investors:

• Seeking an estimated 4% annual yield target on physical bullion.
• Accessing the $22 trillion global gold market via tokenization.
• Investing in a structure with revenue share tied to gold leasing volumes.

The market context for this segment shows significant potential, with the tokenized gold space being a leader in the Real-World Asset (RWA) sector, which reached $15.2 billion by the end of 2024. Analysts are predicting a 73.3% rise in BioSig Technologies, Inc. (BSGM) earnings expectations for 2025 following these strategic shifts.

Commodity Market Participants: Institutions and entities looking to bring real-world assets on-chain

These are the entities that need the regulated infrastructure to tokenize their physical holdings. BioSig Technologies, Inc. (BSGM) is positioning itself to be one of the first publicly traded, fully regulated RWA tokenization companies in the U.S. by acquiring a FINRA and SEC-registered broker-dealer.

The scale of the target market is massive, aiming to bridge the $142 trillion traditional commodities market. Gold itself has a daily trading volume cited at $233 billion.

Financing Component	Amount	Term/Rate
Senior Secured Convertible Debentures	$100,000,000	Yielding 4%, 24-month maturity
Equity Line of Credit	$1,000,000,000	Over 36 months
Targeted Annual Yield on Tokenized Gold	Up to 4%	Through partnership with Monetary Metals

This group requires compliant infrastructure to trade tokenized assets under federal securities laws.

Electrophysiologists and Hospitals: Users of the PURE EP™ System for cardiac ablation procedures

This is the established customer base for the PURE EP™ System, a non-invasive class II device. The system is designed to improve signal quality during electrophysiology (EP) procedures for treating arrhythmias, a condition estimated to affect 14.4 million Americans.

Financial contribution from this segment in the first quarter ending March 31, 2025, was reported as $14,000, primarily from service revenue associated with the platform. Total Revenue for Fiscal Year 2024 was $40,000.

The value proposition is validated by clinical performance metrics:

• Electrophysiologists rated PURE EP™ as superior to conventional systems for 75.2% of signal samples in a blinded study.
• The PURE EP™ subscriber community includes two of the top three U.S. health systems in cardiology.
• Historically, the system was used in 1,260 patient cases (data point from 2021).

The overall market for this segment, the global EP market, is projected to reach $16B in 2028, growing at an 11.2% rate. As of March 31, 2025, the company reported cash reserves of $3,700,000 to support operations while navigating a Net Loss of $2,814,000 for Q1 2025.

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Cost Structure

You're looking at the cost side of BioSig Technologies, Inc.'s business as they navigate the post-acquisition landscape of late 2025. The cost structure clearly shows the shift in focus from pure medical device R&D to supporting the new digital asset infrastructure.

General and Administrative (G&A) Expenses took a significant jump. For the third quarter ending September 30, 2025, G&A soared to $4.619 million. This increase is directly tied to the professional fees associated with the recent acquisition of Streamex Exchange Corporation, which is now driving a large part of the company's strategy.

Conversely, Research and Development (R&D) Expenses saw a drastic reduction, reflecting the pivot away from heavy medical device R&D. In Q3 2025, R&D expenses plummeted to just $6,000. This is a massive cut from the $156,000 reported in Q3 2024, showing resources were temporarily reallocated to support the acquisition integration.

The debt load from the new financing introduces a fixed interest cost. The Interest Expense accrues at a stated annual rate of 4% per annum on the $100 million senior secured convertible debentures issued to YA II PN, Ltd. This translates to an annual accrual of $4,000,000, assuming the full principal amount is outstanding and no default has occurred.

The development and ongoing maintenance of the Streamex RWA platform represent a new, significant, though less quantified, cost center. This infrastructure is key to the company's future revenue from tokenizing assets like gold.

Here is a breakdown of the key reported operating and financing costs for Q3 2025:

Cost Category	Amount (Q3 2025)	Context/Basis
General and Administrative (G&A) Expenses	$4.619 million	Driven by acquisition-related professional fees.
Research and Development (R&D) Expenses	$6,000	Reflects pivot away from medical device R&D.
Annual Interest Accrual (Debt)	$4.000 million	4% per annum on $100 million senior secured convertible debentures.
Depreciation and Amortization	$1.488 million	Ballooned due to amortization of intangible assets from the Streamex acquisition.

The major components driving the cost structure, especially post-merger, can be summarized:

• General and Administrative costs soared to $4.619 million in Q3 2025.
• R&D expenses drastically reduced to $6,000 for the quarter.
• Annual interest accrues at 4% on the $100 million debentures.
• Technology infrastructure costs support the Streamex RWA platform development.
• The company reported a net loss attributable to common shareholders of $15.586 million for the three months ended September 30, 2025.

Finance: draft 13-week cash view by Friday.

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Revenue Streams

You're looking at the revenue picture for BioSig Technologies, Inc. following the major strategic pivot via the Streamex Exchange merger. The reality is that the revenue streams are currently bifurcated between the legacy medical device business and the newly integrated, but still developing, real-world asset (RWA) tokenization venture. It's a story of capital infusion funding the build-out of the new model.

RWA Tokenization Fees

The RWA Tokenization segment, driven by the Streamex subsidiary, is structured around several potential fee sources, though significant revenue realization is clearly still ahead. Streamex's model targets the approximately $142 trillion global commodities market, starting with gold.

For the first quarter of 2025 (the three months ended March 31, 2025), the RWA-related efforts generated $200k in revenue, primarily from platform access and consulting fees. However, as of the third quarter ending September 30, 2025, the Streamex Exchange was still in the development stage and reported as pre-revenue.

The intended fee structure for RWA Tokenization includes:

• Fees generated from tokenizing Gold deliveries.
• Royalties and real estate tokenization fees.
• Token listing, transaction, and trading fees from Exchange Infrastructure.
• Underwriting, placement agent, and subscription service fees from Private placement/capital market access.

Medical Device Sales

Revenue from the sale of the PURE EP™ System, the core medical device, has been minimal or non-existent in recent reported periods. For the three months ending September 30, 2025, BioSig Technologies, Inc. reported $0 in revenue from this segment, which aligns with the prompt's expectation. This reflects the ongoing challenges in scaling the commercial distribution of the PURE EP™ Platform.

Service Revenue

Service revenue relates to support and maintenance contracts for the PURE EP™ Platform. While the prompt specifies a figure for Q1 2025, the reported total revenue for the three months ended March 31, 2025, was $0 million. Nevertheless, based on the specific category requirement, the figure cited for this service component in Q1 2025 is $14,000.

Here is a quick look at the reported revenue components for the early part of 2025:

Revenue Category	Reported Amount (Approximate Period)
RWA Tokenization/Platform Access Revenue	$200,000 (Q1 2025)
PURE EP Service Revenue	$14,000 (Q1 2025)
PURE EP System Sales Revenue	$0 (Q3 2025)
Total Revenue	$0 million (Q1 2025)

Financing Proceeds

Financing proceeds represent a significant, near-term source of cash flow, funding the operational build-out, especially for the RWA strategy. BioSig Technologies, Inc. secured substantial capital in the second half of 2025.

Key financing events include:

• A growth financing package announced in July 2025, totaling up to $1.1 billion.
• This $1.1 billion package is comprised of $100 million in senior secured convertible debentures and a $1 billion equity line of credit over 36 months.
• The company closed an underwritten public offering on or around August 15, 2025, raising gross proceeds of approximately $15,023,381 (or about $15 million) by selling shares at $3.90 per share.
• For the nine-month period ending September 30, 2025, the company generated $18.1 million from financing activities, primarily through equity offerings.

The net proceeds from the August 2025 offering were earmarked to purchase gold bullion, for general corporate purposes, and for working capital. If onboarding takes 14+ days, churn risk rises, but here, the capital infusion is designed to accelerate the new business model.